We expand business to ophthalmology Tübingen, Germany, February 2014. Synovo, a company focused on drug discovery and preclinical development, today announced the strategic decision to extend its service portfolio on ophthalmic indications. Read more Synovo wird Anbieter für Dienstleistungen und Lösungen für Forschung und Entwicklung in der Augenheilkunde Tübingen, Februar 2014. Synovo, Spezialist für Identifikation […]
Synovo 10 years anniversary on Nov 2014 was a total success. Thank you!
Orphan designation for SYD003 for the treatment of pancreatic cancer. Granted by the European Medicines Agency (EMA) on 22 August 2014 and by the US Food and Drug Administration (FDA) on 20 October 2014.
Our compound SYD0073 has been granted orphan designation (EU/3/14/1239) by the European Medicines Agency (EMA) for the treatment of cystic fibrosis.